Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

De IPLA-OVCA-studie, intra-peritoneale lokale anesthesie bij eierstokkanker (IPLA-OVCA)

25 september 2026 bijgewerkt door: Sahar Salehi, Karolinska Institutet

Een gerandomiseerde dubbelblinde, multicenter studie om het tijdsinterval tussen cytoreductieve chirurgie en adjuvante chemotherapie te beoordelen na toediening van lokaal anestheticum intraperitoneaal/perioperatief bij gevorderde epitheliale ovariumkanker

Surgery and chemotherapy combined constitute first line treatment in women with advanced ovarian cancer. The aim of surgery apart from staging is cytoreduction, i.e. surgical resection of tumour. Radical resection of all tumour visible by the naked eye followed by adjuvant chemotherapy is associated with best chance of prolonged survival. However, because of tumour dissemination in the peritoneal cavity, radical surgery is often very extensive with surgery in all quadrants of the abdomen and multi-organ resection with substantial risk of postoperative severe complications and subsequent delay in administration of adjuvant chemotherapy. Longer time-interval between surgery to start of adjuvant chemotherapy has been associated with decrease in survival.

Surgery presents opportunities not only for eradicating tumours but, paradoxically, also for proliferation and invasion of residual cancer cells. It increases the shedding of malignant cells into the blood and lymphatic circulations, inhibits their apoptosis and potentiates their invasion capacity. Additionally, the immune system, the inflammatory system and the neuroendocrine system react to surgery with important changes, which have been proven to promote progression of cancer. Several anaesthesia-related factors play an important role in perioperative tumorigenesis such as inhalational anaesthetics, opiate analgesics, local anaesthetics and regional anaesthesia, all of which may impact short-term morbidity and long-term mortality. A previous randomized placebo-controlled pilot study suggests that women who receive local anesthetics intraperitoneally preoperatively have a significantly decreased time-interval to initiation of adjuvant chemotherapy.

In a prospective, randomised, multi-centre study, we plan to further assess if intraperitoneal local anaesthetics administered perioperatively during 72 h leads to early start of chemotherapy compared to placebo in patients undergoing cytoreductive surgery for FIGO stage III-IV ovarian cancer.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Epithelial ovarian cancer (EOC) is the common term for cancer that originate from the surface of the ovary, lining of the fallopian tube and the peritoneum. There are different histopathological subtypes with high grade serous adenocarcinomas being the most prevalent (70%) followed by endometrioid (10%), clear cell (10%), low-grade serous (5%) and mucinous adenocarcinomas (3%).The pattern of dissemination is foremost through early exfoliation or seeding of tumour-cells in the peritoneum (carcinomatosis) and the majority of women have advanced stage disease at presentation, why ovarian cancer is the gynecologic malignancy with highest mortality.

Ovarian cancer affects 295 000 women every year globally and causes 185 000 cancer-related deaths annually . The highest incidence is seen in Northern Europe and North America and the lowest in South East Asia and parts of Africa. In the Nordic countries 2300 women are diagnosed annually and the corresponding number in Sweden is 700. Ovarian cancer constitutes 3% of all female cancers in Sweden and the risk of developing disease before the age of 75 is 1.1%. A decline in incidence is evident since the 1970s most probably due to increase in use of contraceptive pills but also change in criteria for diagnosis (an adnexal biopsy is mandatory for diagnosis today). The median age at diagnosis is 63 years.

Risk-factors include genetic mutations, family history, hormone replacement therapy and endometriosis. Pregnancy, lactation, contraceptive pills, sterilization, salpingectomy, hysterectomy and salpingoophorectomy are all factors associated with decreased risk of developing EOC.

Staging of ovarian cancer is surgical and according to the International Federation of Gynecology and Obstetrics (FIGO), latest revised in 2014 (7). In stage III and IV, advanced ovarian cancer, extra-pelvic dissemination is evident. Stage of disease is a strong prognostic factor for survival. The total 5-year relative survival in Sweden is 50% but ranges from 90% for stage I to 20% for stage IV. However, treatment is also an important prognostic factor and may increase survival even in advanced stage.

Surgical treatment of advanced EOC is often accompanied by a severe inflammatory and immuno-compromised perioperative course associated with early morbidity, delayed rehabilitation and, sometimes, delayed start of chemotherapy. Early start of chemotherapy has been repeatedly associated with improved survival. For this reason, perioperative factors such as choice of anaesthesia and analgesia and fluid replacement may be important.

Tumorigenesis and the perioperative environment Surgery, perioperative stress and anaesthesia may all modulate the immuno-surveillance mechanisms and compromise host defences that normally maintain a balance between immunity & tumorigenesis. There is increasing evidence that surgery itself may promote the recurrence and metastases of cancer, which depends largely on the tumour's ability to metastasise, combined with the host immunity and inflammatory response. Natural killer (NK) cells act as a primary defence against perioperative cancer metastases. Negative effects of anaesthetics and analgesics on NK-cell activity may promote pro-inflammatory effects and may also activate cancer cell survival pathways. Additionally, concentrations of tumour-related anti-angiogenic factors are decreased while angiogenic factors such as vascular endothelial growth factor (VEGF) are increased. Hypoxia inducing factor (HIF-1) is a transcriptional factor that has also been shown to play an important role for tumour survival. Hypoxia in solid tumours leads to activation of HIF-1, which in turn increases cancer cell survival . Similarly, hyperoxia may, paradoxically, lead to activation of HIF-1 and potentially worsen long-term survival. Inhalational anaesthetics but not propofol have been shown to affect VEGF as well as transforming growth factor-beta (TGF-β) in patients undergoing breast surgery that may affect long-term survival. VEGF and TGF-β play a significant role in establishing tumour blood supply and cell proliferation. Other factors such as surgical stress, blood transfusions, hypothermia, hyperglycaemia, and postoperative pain may also affect immunity and the tumour microenvironment.

Role of anaesthetics and analgesics in cancer metastases Preventing a major systemic inflammatory response and preserving immuno-surveillance in the perioperative period are fundamental in promoting improved postoperative outcome in cancer surgery. The severity of injury correlates with the magnitude of inflammation. In vitro studies have shown that amide local anaesthetics have cytotoxic activity, which could prove to be beneficial in preventing cancer recurrence. These potential cytotoxic effects of LA may effectively reduce postoperative morbidity and promote early start of chemotherapy. Anaesthetic drugs, specifically inhalation anaesthetics, impair numerous immune functions, including those of neutrophils, macrophages, dendritic cells, T-cell, and natural killer (NK) cells. Upregulation of hypoxia-inducible-factors (HIF) in tumour cells by volatile anaesthetics may contribute to a tumour's recurrence by stimulating cytoprotective or pro-tumorigenic behaviour in residual cells. However, propofol may not depress the immune function and does not upregulate synthesis of HIF. Opioid analgesics inhibit both cellular and humoral immune function, increase angiogenesis, and promote breast tumour growth in rodents. Opioids interfere with immune function by depressing NK cell activity . The use of epidural anaesthesia and analgesia thus prevents the stress response to surgery, reduces the need for opiates and may prolong survival.

Fluid dynamics and early recovery Fluid optimization remains a challenge because of several factors: preoperative fluid shifts and accumulation of ascitic fluid, low preoperative albumin from malnutrition, as well as perioperative fluid and blood loss. Both hypo- and hypervolemia have been shown to have adverse effects and may delay recovery and start of chemotherapy and a large prospective, randomised study concluded that hypovolemia may even lead to renal insufficiency.

The primary objective of this Phase 3 double blind placebo controlled trial is to investigate if local anesthetics administered intraperitoneally perioperatively at time of upfront surgery for advanced ovarian cancer reduces the time-interval between surgery and adjuvant chemotherapy.

Secondary objectives are to investigate, postoperative morbidity, complications and long term survival.

The trial entails a translational part with the following specific aims:

I. To examine if surgical peritoneal stress evolves during the course of surgery, as measured by pro-inflammatory cytokines and biomarkers in the mesothelium, tumour tissues and blood, coupled to analysis of the circulating tumour DNA II. To test if intraperitoneally administered anti-inflammatory analgesics may reduce the (mesothelial) inflammation.

III. To use functional ex vivo assays for exploring how the above identified surgical tissue responses and induced or inhibited pathways affect the aggressive EOC cell functions and properties including tumour invasion and chemo-resistance.

Studietype

Ingrijpend

Inschrijving (Geschat)

220

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Stockholm, Zweden, 17176
        • Karolinska Hospital, Solna

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • ASA I-III
  • Scheduled for upfront cytoreductive surgery for presumed stage III or IV epithelial ovarian cancer
  • Signed written informed consent

Exclusion Criteria:

  • Contraindication to epidural anesthesia
  • Allergy to any component drugs used during epidural or intraperitoneal anesthesia (Ropivacaine, Sufentanil)
  • Uncontrolled renal, liver, heart failure or ischemic heart disease
  • Speech, language or cognitive difficulties
  • Women in whom cytoreductive surgery is not attempted at time of upfront laparotomy due to extent of disease

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Placebo-vergelijker: Placebo

Normal saline administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours

Placebo will be administered intraperitoneally

Andere namen:
  • Normale zoutoplossing
Experimenteel: Experimental

Local anesthetic (ropivacaine) administered intraperitoneally at defined times during upfront surgery and intermittently postoperatively for 72 hours

Experimental drug will be administered intraperitoneally

Andere namen:
  • Narop

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Time-interval from upfront surgery to adjuvant chemotherapy
Tijdsspanne: Number of days to start of adjuvant chemotherapy (0 - 60 days)

Days from surgery to first infusion of adjuvant chemotherapy

Number of days to start of adjuvant chemotherapy (0 - 60 days)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Postoperative complications
Tijdsspanne: 30 days postoperatively

Assessed according to the Clavien-Dindo Nomenclature

30 days postoperatively
Overall survival
Tijdsspanne: 3 and 5 years after surgery

Death of any reason

3 and 5 years after surgery
Postoperative quality of recovery
Tijdsspanne: Perioperatively

As measured by validated instruments

Perioperatively
Postoperative morbidity
Tijdsspanne: Perioperatively

As measured by validated instruments

Perioperatively

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Sahar Salehi, MD, PhD, Karolinska Institute and Karolinska University Hospital

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 augustus 2020

Primaire voltooiing (Geschat)

28 september 2028

Studie voltooiing (Geschat)

28 september 2029

Studieregistratiedata

Eerst ingediend

19 augustus 2019

Eerst ingediend dat voldeed aan de QC-criteria

20 augustus 2019

Eerst geplaatst (Werkelijk)

22 augustus 2019

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 20190729

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

All study data will be retained at site of patient recruitment. Primary investigator and statistician will only have access to coded patient identity

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .